IldikoLingvayMDMPH, MSCS

Endocrinology • Dallas, TX

Diabetes, Obesity, Thyroid

Professor of Internal Medicine/Endocrinology at University of Texas Southwestern Medical Center, Dallas, TX

Join to view full profile

Dr. Lingvay is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lingvay's full profile

Already have an account?

Office
5323 Harry Hines Boulevard
Dallas, TX 75390
Phone+1 214-645-2800

Fax+1 214-645-2828

Summary

Dr. Ildiko Lingvay is an endocrinologist in Dallas, TX and is affiliated with multiple hospitals in the area, including University of Texas Southwestern Medical Center, William P. Clements, Jr. University Hospital, and Parkland Health & Hospital System. She received her medical degree from Carol Davila University of Medicine and Pharmacy and has been in practice 19 years. She specializes in diabetes, lipid metabolism, and thyroid.

Education & Training

University of Texas Southwestern Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 2002 - 2005
Texas Tech University (Permian Basin)Residency, Internal Medicine, 1999 - 2002
Carol Davila University of Medicine and PharmacyClass of 1998

Certifications & Licensure

TX State Medical License 2002 - 2025
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
American Board of Obesity Medicine Obesity Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Preservation of Beta-cell Function in Type 2 Diabetes Mellitus Start of enrollment: 2003 Nov 01
Completed
Not Applicable
Role of Pancreatic Triglyceride Content in Beta-cell Function Start of enrollment: 2007 Sep 01
Completed
Changes in Ectopic Fat Following Surgically Induced Weight Loss Start of enrollment: 2008 Aug 01
Completed
Diabetes and Gastric By- Pass Start of enrollment: 2010 Jun 01
Completed
Adding Liraglutide to High Dose Insulin: Breaking the Cycle Start of enrollment: 2012 Jan 01
Completed
Phase 4
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese Start of enrollment: 2012 Dec 01
Terminated
Not Applicable
The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study Start of enrollment: 2014 Nov 01
Completed
Phase 4
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease Start of enrollment: 2024 May 01
Not yet recruiting
Phase 3
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Glycemic Management and Individualized Diabetes Care in Dialysis-Dependent Kidney Failure.
Klara R Klein, Ildiko Lingvay, Katherine R Tuttle, Jennifer E Flythe
Diabetes Care. 2025-02-01
Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial.
Ildiko Lingvay, Malik Benamar, Liming Chen, Ariel Fu, Esteban Jódar
Diabetologia. 2025-01-17
Derivation and Validation of D-RISK: An Electronic Health Record-Driven Risk Score to Detect Undiagnosed Dysglycemia in Clinical Practice.
Michael E Bowen, Ildiko Lingvay, Luigi Meneghini, Brett Moran, Noel O Santini
Diabetes Care. 2025-01-17

Journal Articles

Once-Weekly Semaglutide in Adults with Overweight or Obesity
Ildiko Lingvay, Barbara M Mcgowan, Julio Rosenstock, Marie TD Tran, Thomas A Wadden, The New England Journal of Medicine
A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients with Type 2 Diabetes Suboptimally Controlled on Diet and Exe...
Ildiko Lingvay, Cyrus V Desouza, Diabetes Care

Press Mentions

A Powerhouse of Obesity Research – Then and NowSeptember 20th, 2024
Type 1 Diabetes and Use of ‘Off-Label’ Drugs: Benefits, but Concerns, TooFebruary 20th, 2023
Study Provides a Rare View of Real-World Use of off-Label Drugs Prescribed for Type 1 DiabetesFebruary 16th, 2023
Join now to see all

Grant Support

Role Of Pancreatic Triglycerides In Beta-Cell DysfunctionNational Center For Research Resources2007–2011

Other Languages

Romanian, Hungarian